News | April 01, 2025
Briefs: AstraZeneca Pharma India, Pharmaids and Dr. Agarwal's Health Care
AstraZeneca Pharma India discontinues manufacturing of Imdur
AstraZeneca Pharma India discontinues manufacturing of Imdur
This expanded partnership helps Evonik to streamline its distribution model in Asia Pacific
This will lead to the consolidation and optimization of the company's operations related to the manufacturing of ampoules and vials
Peter Bains has over three decades of experience in the biotech and pharmaceutical industry
Pascal Villemagne has announced his intent to step down at the end of March 2025, to take on a new challenge in his professional career.
Dyrupeg will be available as 6 mg solution for injection in prefilled syringe and is intended for the reduction in the duration of neutropenia
Recommendation based on results of Phase 3 CheckMate -9DW clinical trial demonstrating statistically significant and clinically meaningful improvement in overall survival with Opdivo plus Yervoy compared to investigator’s choice of lenvatinib or sorafenib in this patient population
Jubilant Cadista will submit an appropriate action plan to the USFDA on these observations
The order, part of an international framework agreement is to be executed between February to April, 2025
We are witnessing a steady and sustainable growth in the country as the Q2 revenue from operations increased by 31%
Subscribe To Our Newsletter & Stay Updated
